期刊
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
卷 105, 期 2, 页码 189-193出版社
OXFORD UNIV PRESS
DOI: 10.1093/qjmed/hcq248
关键词
-
资金
- National Institute for Health Research (NIHR)
Maternal thyrotoxicosis, predominantly secondary to Graves' disease, affects 0.2% of all pregnancies. The Endocrine Society guidelines recommend the use of propylthiouracil as a first-line drug for thyrotoxicosis in pregnancy because of associations between carbimazole or methimazole and congenital anomalies. However, recent studies have highlighted the risk of severe liver injury with propylthiouracil. Here, we report another case with multiple congenital anomalies following in utero exposure to carbimazole and review the literature to consider the risks and benefits of available pharmacological treatments for thyrotoxicosis in pregnancy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据